Korro Bio Inc
KRRO33.840USD
+1.270+3.90%
Handelsschluss 11/07, 16:00（ET）Kurse um 15 Minuten verzögert
317.79MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Korro Bio Inc Unternehmen
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Korro Bio Inc Informationen
BörsenkürzelKRRO
Name des UnternehmensKorro Bio Inc
IPO-datumOct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Anzahl der mitarbeiter104
WertpapierartOrdinary Share
GeschäftsjahresendeOct 03
AddresseOne Kendall Square. Building 600-700
StadtCAMBRIDGE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02139
Telefon16174681999
Websitehttps://www.korrobio.com/
BörsenkürzelKRRO
IPO-datumOct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Führungskräfte von Korro Bio Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
Dr. Katharine (Kate) Knobil, M.D.
Dr. Katharine (Kate) Knobil, M.D.
Independent Director
Independent Director
--
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Umsatzaufteilung
FY2025Q2
FY2025Q1
FY2024
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
1.46M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: 8 hours ago
Aktualisiert: 8 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Fidelity Management & Research Company LLC
6.81%
Driehaus Capital Management, LLC
6.19%
Platanus Investment LLC
5.75%
Andere
57.53%
Aktionäre
Aktionäre
Anteil
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Fidelity Management & Research Company LLC
6.81%
Driehaus Capital Management, LLC
6.19%
Platanus Investment LLC
5.75%
Andere
57.53%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
30.67%
Hedge Fund
27.09%
Venture Capital
23.72%
Investment Advisor/Hedge Fund
13.96%
Corporation
5.75%
Research Firm
1.37%
Individual Investor
0.42%
Private Equity
0.34%
Pension Fund
0.12%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
186
9.14M
97.37%
-1.25M
2025Q2
186
10.38M
110.55%
-200.85K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
2023Q3
223
264.10K
35.84%
-47.15K
2023Q2
235
150.53K
21.10%
-156.09K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Atlas Venture
1.14M
12.11%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
1.09M
11.62%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
639.22K
6.81%
-4.05K
-0.63%
Jun 30, 2025
Driehaus Capital Management, LLC
580.86K
6.19%
-1.59K
-0.27%
Jun 30, 2025
Platanus Investment LLC
540.16K
5.75%
--
--
Apr 15, 2025
Point72 Asset Management, L.P.
540.07K
5.75%
+19.18K
+3.68%
Jun 30, 2025
Cormorant Asset Management, LP
465.00K
4.95%
+84.70K
+22.27%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
423.16K
4.51%
+15.35K
+3.76%
Jun 30, 2025
Invus Public Equities Advisors, LLC
418.83K
4.46%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
386.74K
4.12%
+4.94K
+1.29%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Name
Anteil
iShares Micro-Cap ETF
0.07%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.07%
Avantis US Small Cap Equity ETF
Anteil0.02%
iShares Russell 2000 Value ETF
Anteil0.02%
ProShares UltraPro Russell2000
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%
iShares Russell 2000 ETF
Anteil0.01%
Global X Russell 2000 ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
SPDR Portfolio MSCI Global Stock Market ETF
Anteil0%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Datum
Art
Verhältnis
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
